BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
407 results:

  • 1. VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.
    Lee H; Zhuang L; Gan B
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618953
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Designing a predictive Framework: Immune-Related Gene-Based nomogram and prognostic model for kidney renal papillary cell carcinoma.
    Lim A; Edderkaoui M; Zhang Y; Wang Q; Wang R; Pandol SJ; Ou Y
    Int Immunopharmacol; 2024 Apr; 131():111878. PubMed ID: 38493693
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Pterostilbene and 6-shogaol exhibit inhibitory effects on sunitinib resistance and motility by suppressing the RLIP76-initiated Ras/ERK and akt/mTOR pathways in renal cancer cells.
    Chiang IC; Chen SY; Hsu YH; Shahidi F; Yen GC
    Eur J Pharmacol; 2024 Mar; 967():176393. PubMed ID: 38325792
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent akt pathway activation.
    Liu T; Xiang W; Chen Z; Wang G; Cao R; Zhou F; Meng Z; Luo Y; Chen L
    Cell Death Dis; 2023 Nov; 14(11):774. PubMed ID: 38008826
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
    Li S; Yi Z; Li M; Zhu Z
    J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
    Aweys H; Lewis D; Sheriff M; Rabbani RD; Lapitan P; Sanchez E; Papadopoulos V; Ghose A; Boussios S
    Anticancer Res; 2023 Nov; 43(11):4781-4792. PubMed ID: 37909991
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
    Sohel M
    Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Exploring the material basis and mechanism of action of clinacanthus nutans in treating renal cell carcinoma based on metabolomics and network pharmacology.
    Ye Z; Fang Z; Li D; Lin X; Huang S
    Medicine (Baltimore); 2023 Oct; 102(42):e35675. PubMed ID: 37861516
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
    Grimm MO; Esteban E; Barthélémy P; Schmidinger M; Busch J; Valderrama BP; Charnley N; Schmitz M; Schumacher U; Leucht K; Foller S; Baretton G; Duran I; de Velasco G; Priou F; Maroto P; Albiges L;
    Lancet Oncol; 2023 Nov; 24(11):1252-1265. PubMed ID: 37844597
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
    Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
    J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
    Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
    J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
    Knudsen S; Hansen A; Foegh M; Petersen S; Mekonnen H; Jia L; Shah P; Martin V; Frykman G; Pili R
    PLoS One; 2023; 18(8):e0290681. PubMed ID: 37647320
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Melatonin suppresses akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect.
    Xue KH; Jiang YF; Bai JY; Zhang DZ; Chen YH; Ma JB; Zhu ZJ; Wang X; Guo P
    Redox Rep; 2023 Dec; 28(1):2251234. PubMed ID: 37642220
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
    Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
    Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PI3K/akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
    Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
    Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I.
    Zhang M; Zhu LZ; Yang CJ; Yan JX; Wang ZP; Bai YP; Peng LZ; Luo HB; Zhang ZJ; Li L; Xu CR; Liu YQ
    Bioorg Chem; 2023 Oct; 139():106652. PubMed ID: 37390632
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Macrophage-derived exosomal miR-342-3p promotes the progression of renal cell carcinoma through the NEDD4L/CEP55 axis.
    Feng J; Xu B; Dai C; Wang Y; Xie G; Yang W; Zhang B; Li X; Wang J
    Oncol Res; 2021; 29(5):331-349. PubMed ID: 37305161
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Computational docking and
    Otifi HM; Alshyarba M; Fayi MA; Dera AA; Rajagopalan P
    Oncol Res; 2021; 29(3):217-227. PubMed ID: 37304673
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Precision oncology options in urological cancers].
    Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
    Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CHRM4/akt/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
    Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
    Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 21.